Business
SmooFi Announces Corporate Name Change to NuLife Sciences, Inc. and Stock Symbol Change to "NULF"
SmooFi Announces Corporate Name Change to NuLife Sciences, Inc. and Stock Symbol Change to "NULF".
About this update from Gulf West Security Network Inc.
[{"type":"text","content":"\nSmooFi Announces Corporate Name Change to NuLife Sciences, Inc. and Stock Symbol Change to \"NULF\"\n\nSmooFi Announces Corporate Name Change to NuLife Sciences, Inc. and Stock Symbol Change to \"NULF\"\n\nSAN CLEMENTE, CA--(Marketwired - December 07, 2016) - SmooFi Inc. (OTCQB: SMFI) today announced that FINRA has approved its corporate name change to NuLife Sciences, Inc. as well as a change of the trading symbol of the Company's common stock. Effective Thursday, December 8th, the Company's shares of common stock will commence trading on the OTC Markets under the trading symbol \"NULF\" and CUSIP number 67054M105. The name change was the result of the close of the Asset Purchase Agreement through which NuLife acquired all of the assets of GandTex, LLC, a company with biomedical IP focused on advancing human organ transplant technology and medical research. \"We are moving forward as NuLife Sciences, a name that better reflects our focus on a unique patented proprietary method, the 'NuLife Technique', that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs in human organ transplant,\" said John Hollister, Chief Executive Officer of NuLife Sciences. \"With over 123K candidates waiting for an organ in the U.S. alone, the market need is great with a potential to use discarded or marginal organs. With the Discovery phase completed, we now intend to enter a Preclinical phase involving animal experiments in collaboration with Florida International University and Nova Southeastern University. We look forward to updating investors as our progress moves ahead.\" About NuLife SciencesNuLife Sciences is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method (\"NuLife Technique\") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization. NuLife Sciences will also provi...